Neurocrine Biosciences Director Kevin Gorman Reports PRSU Vesting and Tax Withholding

Executive Summary

On September 15, 2026, Neurocrine Biosciences Inc ($NBIX) director Kevin Charles Gorman filed a Form 4 detailing equity transactions that occurred on September 11, 2026. The transaction involved the vesting of performance restricted stock units (PRSUs) and the subsequent withholding of shares to cover tax liabilities.

---

Transaction Breakdown

1. PRSU Vesting (Code A):

   • Shares Acquired: 14,343 shares of Common Stock
   • Price: $0.00
   • Details: Certification of the achievement of a performance metric under previously granted PRSUs.

2. Tax Withholding (Code F):

   • Shares Disposed: 7,839 shares of Common Stock
   • Price Per Share: $156.22
   • Total Withheld Value: ~$1,224,608.58
   • Details: Automatic withholding by the issuer to satisfy applicable tax obligations; no open-market trade occurred.

---

Ownership Post-Transaction

Following the transactions, Dr. Gorman beneficially owns 517,797 shares directly (held via the Gorman and Blais Family Trust, over which he maintains voting and investment power).

---

Market & Trading Implications

• Significance: Low
• These transactions are standard administrative events related to equity compensation vesting and tax withholding rather than discretionary open-market buying or selling.